Today: 7 February 2026
Subscribe
Browse Category

ASX:CSL News 21 November 2025 - 10 December 2025

CSL Limited (ASX:CSL) Share Price Near $180: Latest News, Analyst Forecasts and 2026 Outlook as at 10 December 2025

CSL Limited (ASX:CSL) Share Price Near $180: Latest News, Analyst Forecasts and 2026 Outlook as at 10 December 2025

CSL Limited (ASX:CSL), the Melbourne‑based plasma and vaccines giant, is finishing 2025 under intense scrutiny from investors, regulators and politicians alike. As of the afternoon of 10 December 2025, CSL shares are trading around A$180–182, after closing at about A$181.82 on 9 December and slipping intraday today to roughly A$181.Intelligent Investor+1 That puts the stock down roughly 30% for the year, one of the weakest annual performances in the company’s modern history.Companies Market Cap Yet brokers’ models and fresh buy‑back activity suggest management and many analysts still see upside into 2026. Below is a rundown of the key news, numbers
10 December 2025
·
Best ASX Stocks to Buy Now (10 December 2025): 10 Australian Shares to Watch After the RBA Pause

Best ASX Stocks to Buy Now (10 December 2025): 10 Australian Shares to Watch After the RBA Pause

Australia’s share market heads into the end of 2025 in a strange mood: the S&P/ASX 200 is holding near record levels above 8,500 points, but leadership has flipped, valuations are resetting, and the Reserve Bank of Australia (RBA) has just signaled that the easy-money era is definitely over.The Inside Advisor+ 1 In this environment, investors are hunting for quality ASX stocks with real earnings power, sensitive valuations, and exposure to long‑term themes like electrification, AI, and the energy transition. Below you’ll find a 10‑stock watchlist of some of the best ASX shares to research right now , based on fresh
10 December 2025
···
CSL Limited (ASX:CSL) Stock Outlook 2026: Is the Biotech Giant Finally a Buy After a 35% Sell-Off?

CSL Limited (ASX:CSL) Stock Outlook 2026: Is the Biotech Giant Finally a Buy After a 35% Sell-Off?

As of 9 December 2025 CSL Limited, long considered one of the most reliable growth names on the ASX, has just lived through one of the ugliest years in its listed history. After profit downgrades, a delayed spin-off, falling US vaccination rates and a shareholder revolt over executive pay, the stock is trading far below its early‑2025 highs. Yet underneath the market drama, earnings are still growing, the balance sheet remains strong, and analysts – almost unanimously – still see upside. This article pulls together the latest news, forecasts and analysis on CSL shares as at 9 December 2025, to
9 December 2025
CSL Limited (ASX:CSL) Share Price, Buyback and 2026 Outlook: Latest News and Forecasts as at 5 December 2025

CSL Limited (ASX:CSL) Share Price, Buyback and 2026 Outlook: Latest News and Forecasts as at 5 December 2025

CSL Limited’s share price is still nursing some heavy bruises, but under the surface the story in December 2025 is more “complex reboot” than simple “fallen giant”. On 5 December 2025, the ASX healthcare heavyweight is trading near multi‑year lows after a brutal few months of restructuring, a guidance cut and a delayed vaccines spin‑off. At the same time, CSL is ramping up a large on‑market buyback, opening a $1 billion vaccine and antivenom plant in Melbourne and reiterating medium‑term profit growth targets. Global Newsroom | CSL+1 This article pulls together the latest price action, company announcements, analyst forecasts and
5 December 2025
···
CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

Updated: 4 December 2025 CSL Limited (ASX:CSL), the Australian biotech heavyweight, is trading around A$183 per share on 4 December 2025 after one of the most bruising years in its modern history. The company has delivered solid profit growth, announced thousands of job cuts, delayed a major spin‑off, launched a A$750 million buy‑back and opened a A$1 billion cell‑based vaccine and antivenom plant in Melbourne – all while its share price has fallen by roughly a third. Intelligent Investor+2Global Newsroom | CSL+2 Against that backdrop, investors are trying to decide whether CSL is now a long‑term bargain or a restructuring
4 December 2025
·
CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

Updated: 2 December 2025 CSL Limited’s share price has spent most of 2025 in the sin bin, but behind the drawdown sits a mix of solid earnings growth, a radical restructuring, a forthcoming spin‑off of its vaccines arm and fresh news today about a major new vaccine plant and an active on‑market buyback. Together, these developments are reshaping the investment story for one of the ASX’s most important healthcare names. Where the CSL share price stands today At around midday on 2 December 2025, CSL shares were trading near A$182–183, with one widely used data source showing a last price
2 December 2025
·
CSL Limited (ASX:CSL) Share Price, Latest News and 2026 Outlook as of 1 December 2025

CSL Limited (ASX:CSL) Share Price, Latest News and 2026 Outlook as of 1 December 2025

CSL Limited heads into the 1 December 2025 ASX session as one of Australia’s most closely watched blue‑chip stocks. After a year of guidance cuts, a delayed vaccine spin‑off and a shareholder revolt, the biotech giant trades around the mid‑A$180s – roughly a third below where it started 2025 – despite solid profit growth, an aggressive cost‑cutting program and a multi‑year share buyback. TechStock²+1 This article summarises the latest CSL share price, the key news driving sentiment, current forecasts and analyst views as at 1 December 2025. CSL share price snapshot on 1 December 2025 CSL last changed hands at
1 December 2025
··
CSL Limited (ASX:CSL) Shares: Cost Cuts, Buyback and US Expansion – What to Watch Before the ASX Opens on 1 December 2025

CSL Limited (ASX:CSL) Shares: Cost Cuts, Buyback and US Expansion – What to Watch Before the ASX Opens on 1 December 2025

CSL Limited (ASX:CSL) goes into Monday’s ASX open on 1 December 2025 as one of the market’s most hotly debated blue chips – bruised by profit downgrades and a delayed spin‑off, yet backed by a large buyback, a US$1.5 billion expansion plan and several analysts calling the stock undervalued. Reuters+3Reuters+3Simply Wall St+3 Below is a rundown of the latest CSL share price, news, forecasts and analysis from 28–30 November 2025, and how they shape expectations ahead of Monday’s session. CSL (ASX:CSL) share price snapshot before the 1 December 2025 open CSL last traded around A$186.30 per share, based on Friday
30 November 2025
··
CSL Limited (ASX:CSL) Stock Today: Buyback Update, Share Price Action and Outlook – 27 November 2025

CSL Limited (ASX:CSL) Stock Today: Buyback Update, Share Price Action and Outlook – 27 November 2025

Sydney – Thursday, 27 November 2025 CSL Limited (ASX:CSL) enters the final month of 2025 still nursing one of the toughest years in its history. After profit downgrades, a delayed vaccine spin‑off and a brutal share-price slump, the biotech giant is leaning on a A$750 million on‑market buyback and fresh investment plans to steady investor nerves. Today’s news flow is dominated by a new ASX filing detailing the latest progress of that buyback, alongside fresh commentary from analysts weighing whether CSL’s share price slide has finally gone far enough. CSL share price today: trading around A$183 after a heavy 2025
27 November 2025
··
CSL Limited (ASX: CSL) pre‑open brief for 17 November 2025: Buy‑back in full swing, Seqirus spin‑off delayed, guidance cut — here’s what matters

CSL Share Price Update: Buy‑Back Acceleration and US$1.5 Billion US Expansion Shape Outlook on 21 November 2025

MELBOURNE / SYDNEY – 21 November 2025 – CSL Limited (ASX: CSL), the Australian biopharmaceutical giant and long‑time ASX 20 heavyweight, entered Friday’s trade with two dominant storylines: a fresh on‑market share buy‑back update lodged with the ASX this morning, and the market’s ongoing reaction to its recently announced US$1.5 billion investment program in US plasma‑derived therapy manufacturing. Global Newsroom | CSL+3Australian Securities Exchange+3AFR Company Announcements+3 At the same time, the CSL share price remains deep in recovery mode after a brutal year. External research estimates the stock is down roughly 36% year to date, turning what was once a market darling into a
21 November 2025
1 2 3

Stock Market Today

HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

7 February 2026
HSBC shares closed up 2.2% at £13.06 on Friday, reversing Thursday’s drop as traders weighed possible Bank of England rate cuts and awaited the bank’s annual results on Feb. 25. The FTSE 100 rose 0.6%, with major UK banks also gaining. HSBC is also preparing to cut some banker bonuses and push out underperformers amid a cost reset. Key UK, U.S., and euro zone economic data are due next week.
Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

7 February 2026
Agricultural Bank of China’s A shares closed down 0.45% at 6.67 yuan in Shanghai Friday, with turnover at 2.24 billion yuan. The bank’s A-share capital remained unchanged at 319.24 billion shares as of Jan. 31. Mainland and Hong Kong stocks fell after a global tech selloff and a sharp drop in silver futures. China’s January CPI data is due Feb. 11, with trading expected to thin ahead of the Lunar New Year break.
Palantir stock price rebounds after AI shakeout — what traders watch next week

Palantir stock price rebounds after AI shakeout — what traders watch next week

7 February 2026
Palantir Technologies shares rose 4.5% to $135.90 Friday after reporting a 70% jump in Q4 revenue to $1.407 billion and forecasting 61% revenue growth in 2026. The stock rebounded from a 6.8% drop Thursday, triggered by concerns over Big Tech capital spending and AI’s impact on software demand. A new partnership with Cognizant and U.S. government policy shifts kept Palantir in focus. Director Alexander D. Moore sold 20,000 shares on Feb. 2.
Go toTop